Generate:Biomedicines

AI isn’t just accelerating molecular design—it’s redefining what’s possible. On Tuesday, March 18, at #GTC2025, our co-founder and CTO, Gevorg Grigoryan, joins Nobel Laureate and Caltech professor Frances Arnold, Angela Aristidou of University College of London and Stanford University, and Abe Stern of NVIDIA on the panel "Designing the Future: Protein Engineering, AI, and Responsible Innovation." They will break down the #AI-driven breakthroughs transforming protein science, from structure prediction to de novo design, and tackle the risks, safety challenges, and ethical stakes as AI pushes molecular engineering forward. The future of molecular design is being built now. Don’t miss it: https://lnkd.in/eT2zhcVk #ProgrammingBiology | #NowWeCan

Generative AI isn’t just transforming drug discovery—it’s redefining the modern biotech ecosystem. At the #MontgomerySummit by March Capital, Quentin Hardy led a candid conversation with our CEO, Michael Nally, DIMITRIOS ILIOPOULOS of Athos Therapeutics Inc, and Thore Graepel of Altos Labs on what’s real, what’s next, and how #AI is reshaping medicine. Mike shared how our first two AI-generated assets are already in the clinic, using optimization to refine molecular design and push beyond the limits of traditional biologics. But that’s just the beginning. The same technology is also opening the door to de novo design, creating entirely new medicines with unprecedented possibilities. See where the future is headed: https://lnkd.in/eF5dB5Jc #ProgrammingBiology | #NowWeCan

The Montgomery Summit presented by March Capital is where the boldest ideas in technology, investment, and innovation take center stage. Our CEO, Michael Nally, will be in two discussions on how #AI is driving real impact in biotech and beyond. March 5 at 8:30am PT "Generative AI in Therapeutics: A New Vision for Biology" Mike joins DIMITRIOS ILIOPOULOS of Athos Therapeutics Inc and Thore Graepel of Altos Labs to cut through the hype and explore AI’s role in transforming drug discovery. Moderated by Quentin Hardy of LGTM LLC Communications Services. March 5 at 1:00pm PT "Service as Software: Emerging Vertical Markets for AI" Mike will take the stage with Michael Bergin of Higharc, Mark Lee of MarqVision (YC S21), Rami Karabibar of EvenUp, and moderator Hyun Koo of March Capital to discuss how AI is redefining industries at scale. Don’t just watch the AI revolution—be part of it: https://lnkd.in/dRk9swgi #MontySummit | #GenerativeBiology

What if designing new medicines was as intuitive as creating digital art? On this week's Amazon Web Services (AWS)"Health Innovation Podcast", Tharindi Hapuarachchi, PhD, our VP of Platform Strategy & Operations, joins Sanjit Misra to discuss how #GenerativeBiology is making it possible to create novel proteins with speed, scale, and precision. Tharindi shares how #AI and #MachineLearning are enabling a shift from discovering medicines to intentionally designing them—changing what is possible in therapeutic development. Listen on the Health Podcast Network, or wherever you listen to your podcasts: https://lnkd.in/enJZvM8v #ProgrammingBiology | #AWSHealthPod

Calling all computational protein modeling and design enthusiasts! Join us at "Winter RosettaCon 2025" (Rosetta Commons), where experts in #ProteinDesign, deep learning, structural modeling, and enzyme engineering are driving the field forward. At Generate:Biomedicines, we’re applying these advances to program biology and create better medicines with precision and speed. We’re hosting a career lunch, where you can meet our scientists and engineers, learn about our work, and explore opportunities to join our team. Sign up here: https://lnkd.in/eyKAAcuR. We’re hiring across #AI, #MachineLearning, protein science, and computational biology. One of our open roles is Head of Computational Protein Generation, leading research in AI-driven molecular design and biophysics. Learn more about this role and all our open positions by joining us for lunch or visiting our careers page. #ProgrammingBiology | #NowWeCan | #Hiring

Today, our EVP, R&D, Alexandra Snyder, MD is speaking at the National Academy of Sciences workshop, "Building Access to Tomorrow’s Medicines"—a workshop exploring the transformative potential of #AI and #ML in chemical sciences and drug discovery. The event brings together researchers, policymakers, and stakeholders to examine how AI, automation, and robotics can address data biases, democratize pharmaceutical research, and reduce drug development costs—cutting timelines from decades to years. Alex will share how AI-driven drug discovery is accelerating the path from idea to impact, bringing new possibilities to medicine and setting the foundation for the future of therapeutic innovation. Learn more: https://lnkd.in/gAYtY8pW #ProgrammingBiology | #NowWeCan

Women hold just 22% of AI roles globally, according to World Economic Forum's "Global Gender Gap Report 2024". Yet diverse perspectives are critical to driving innovation—especially in AI-powered drug discovery. At Generate:Biomedicines, AI isn’t just a tool—it’s how we #ProgramBiology to create new medicines. For #InternationalDayOfWomenAndGirlsInScience, we’re highlighting Erin Yang, Ph.D., Hoda Akl, Ph.D, and Tharindi Hapuarachchi, PhD, who are applying #MachineLearning to #ProteinDesign, computational modeling, and platform strategy—advancing what’s possible in drug discovery. Read about their paths into #AI, the role of #mentorship, and the impact of bringing diverse expertise together: https://lnkd.in/ePAPHFZq #WomenInAI | #February11

Piper Sandler's "Virtual TSLP Day" on Friday, February 7 will take a deep dive into the evolving clinical development and treatment landscape for TSLP-targeting therapies in respiratory disease. Our CEO, Michael Nally, and EVP, R&D, Alexandra Snyder, MD, will take part in a fireside chat to discuss innovation, differentiation, and the future of this space. The event will also feature discussions with industry leaders from Amgen, Aclaris Therapeutics, Inc., Apogee Therapeutics, and Upstream Bio. Appreciate Yasmeen Rahimi, PhD, David Amsellem, Chris Raymond, and Ted Tenthoff at Piper Sandler for leading this important conversation. #ProgrammingBiology | #NowWeCan

Last week, #TeamGenerate gathered for a fireside chat with Fiona H. Marshall, President of Biomedical Research at Novartis, and our EVP, R&D, Alexandra Snyder, MD. Fiona shared her perspective on how #GenerativeBiology and #AI are shaping the future of drug discovery. ? “Generative biology has the potential to go beyond traditional methods, allowing us to tackle challenges differently and explore new opportunities in science,” Fiona explained. ? Her visit highlighted the shared vision behind Novartis and Generate’s collaboration, announced last year, to leverage AI-driven technology for next-generation protein therapeutics. The discussion embodied our shared #UnapologeticallyScientific mindset and the need to embrace bold solutions to address unmet medical needs. Learn more about the collaboration: https://lnkd.in/gAMydyTM #ProgrammingBiology | #NowWeCan

What if biology and #AI could unlock solutions to challenges once thought impossible? On #SolveforX, host Manjula Selvarajah speaks with Geoffrey von Maltzahn, one of our co-founders and a Flagship Pioneering partner. Geoff shares how #GenerativeBiology is creating new opportunities in medicine by combining cutting-edge AI with biology to target diseases in ways never before imagined. “At Generate, we’re seeing translational impact—therapies that couldn’t be designed through traditional means,” says Geoff. ?? Don’t miss this bold conversation about the future of medicine: https://lnkd.in/eJPU-6gx #ProgrammingBiology | #NowWeCan